Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2007 1
2008 1
2018 2
2019 1
2022 3
2024 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer.
Li W, Onishi N, Gibbs JE, Wilmes LJ, Le NN, Metanat P, Price ER, Joe BN, Kornak J, Yau C, Wolf DM, Magbanua MJM, LeStage B, van 't Veer LJ, DeMichele AM, Esserman LJ, Hylton NM. Li W, et al. Among authors: gibbs je. Tomography. 2025 Feb 27;11(3):26. doi: 10.3390/tomography11030026. Tomography. 2025. PMID: 40137566 Free PMC article.
Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy.
Li W, Le NN, Onishi N, Newitt DC, Wilmes LJ, Gibbs JE, Carmona-Bozo J, Liang J, Partridge SC, Price ER, Joe BN, Kornak J, Magbanua MJM, Nanda R, LeStage B, Esserman LJ, I-Spy Imaging Working Group, I-Spy Investigator Network, Van't Veer LJ, Hylton NM. Li W, et al. Among authors: gibbs je. Cancers (Basel). 2022 Sep 13;14(18):4436. doi: 10.3390/cancers14184436. Cancers (Basel). 2022. PMID: 36139594 Free PMC article.
Impact of Alternate b-Value Combinations and Metrics on the Predictive Performance and Repeatability of Diffusion-Weighted MRI in Breast Cancer Treatment: Results from the ECOG-ACRIN A6698 Trial.
Partridge SC, Steingrimsson J, Newitt DC, Gibbs JE, Marques HS, Bolan PJ, Boss MA, Chenevert TL, Rosen MA, Hylton NM. Partridge SC, et al. Among authors: gibbs je. Tomography. 2022 Mar 4;8(2):701-717. doi: 10.3390/tomography8020058. Tomography. 2022. PMID: 35314635 Free PMC article.
Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective Study.
Li W, Le NN, Nadkarni R, Onishi N, Wilmes LJ, Gibbs JE, Price ER, Joe BN, Mukhtar RA, Gennatas ED, Kornak J, Magbanua MJM, Van't Veer LJ, LeStage B, Esserman LJ, Hylton NM. Li W, et al. Among authors: gibbs je. Tomography. 2024 Nov 20;10(11):1832-1845. doi: 10.3390/tomography10110134. Tomography. 2024. PMID: 39590943 Free PMC article.
Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.
Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, Hylton NM; ACRIN Trial Team and I-SPY 2 TRIAL Investigators. Newitt DC, et al. Among authors: gibbs je. J Magn Reson Imaging. 2019 Jun;49(6):1617-1628. doi: 10.1002/jmri.26539. Epub 2018 Oct 22. J Magn Reson Imaging. 2019. PMID: 30350329 Free PMC article.
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.
Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Romanoff J, Cimino L, Joe BN, Umphrey HR, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis JS, Esserman LJ, Hylton NM; ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators. Partridge SC, et al. Among authors: gibbs je. Radiology. 2018 Dec;289(3):618-627. doi: 10.1148/radiol.2018180273. Epub 2018 Sep 4. Radiology. 2018. PMID: 30179110 Free PMC article. Clinical Trial.
11 results